We completely disagree with this. This would signify total surrender in the face of a vital challenge for Brazilian Medicine and would constitute a declaration of little faith in the quantity and quality of Brazilian healthcare professionals, including those with master's and doctoral degrees who have already formally qualifi ed, and including those under the supervision of one of the authors cited. It also ignores all the good work developed by the Brazilian Cochrane Center, APM, the Brazilian Medical Association (Associação Médica Brasileira, AMB), the Ministry of Health, the National Agency for Sanitary Surveillance (Agência Nacional de Vigilância Sanitária, ANVISA) etc. Nonetheless, this controversy is good and we are not going to shy away from it. We take the view that everyone will have to agree that it only makes sense to proceed with a technological assessment on a new diagnostic, therapeutic or preventive method, if there is evidence regarding its effi cacy or effectiveness, at least. This is even clearer if there is no proof of its effi ciency and safety, considering that in these evaluations we are generally investigating the advantages of the new product in relation to non-intervention or other options. Therefore, if there is no reasonable evidence that, for example, the treatment has better performance than non-intervention in the real world, there is no justifi cation to continue to evaluate it technologically, with regard to its economic, management and safety characteristics, etc. Good-quality randomized clinical trials are a fundamental step in this process. For instance, if a type of prosthesis or medication is clearly less effective than and not as safe as a similar product, there is no economic evidence that can recommend it, no matter how fi nancially or managerially advantageous the item may be, since safety is essential. Moreover, without safety, there is little room to continue with a more pragmatic assessment. Nor does it make sense to continue with a technological assessment on products when clinical trials on these products have demonstrated that their effect is no better than placebo, for example. A study of ours that mapped out the evidence for fi rstlevel healthcare decisions (Cochrane systematic reviews) ment, which has the aim of achieving more immediate implementation. Hence, adequate mapping of the evidence is essential for the technological assessment of any procedure, and this will resolve a large proportion of the cases. We reemphasize that mapping out the evidence is mandatory for starting the process, and it may often finish the process. When there is evidence that an item is effective and safe, then indeed we can move on to evaluations of the economics, efficiency, management, ethics and so on. 
